Skip to main content


02-03-2023 | Empagliflozin | News

DINAMO: Empagliflozin shows promise for young people with type 2 diabetes

Empagliflozin, but not linagliptin, provides “clinically relevant” improvements in glycemic control versus placebo in children and adolescents with type 2 diabetes, report the DINAMO investigators.

12-06-2022 | Empagliflozin | News

Empagliflozin benefits supported for mid-range ejection fraction

A prespecified analysis of EMPEROR-Preserved indicates benefits of empagliflozin for people with heart failure and mildly reduced or preserved left ventricular ejection fraction.

11-04-2022 | Empagliflozin | News | Article

EMPA-KIDNEY supports SGLT2 inhibition for chronic kidney disease

Treating people with chronic kidney disease with the SGLT2 inhibitor empagliflozin significantly reduces their risk for renal disease progression or cardiovascular mortality, report the EMPA-KIDNEY investigators.

Clinician holding a clear tablet with a heart image - cardiovascular research concept

08-31-2022 | Heart failure | News

‘Strikingly consistent’ evidence for SGLT2 inhibitor benefits across the spectrum of heart failure

SGLT2 inhibitors reduce the risk for adverse outcomes in a broad range of patients with heart failure, suggest findings from a meta-analysis of five randomized placebo-controlled trials.

Healthy breakfast - symbolic image with model

07-21-2022 | Sotagliflozin | News

Sotagliflozin effects differ from empagliflozin only at breakfast

The only notable short-term differences in the effects of sotagliflozin and empagliflozin occur in glucose metabolism after breakfast, show findings from a randomized trial.

05-18-2022 | Empagliflozin | News

Pros and cons with empagliflozin addition to closed-loop insulin

Adding daily empagliflozin to closed-loop insulin delivery improves time in range but also increases ketone levels in people with type 1 diabetes, shows a randomized trial.

03-01-2022 | Empagliflozin | News

Empagliflozin indication extended to all heart failure in USA

Click through to read more on this announcement


02-28-2022 | Empagliflozin | News

EMPULSE shows empagliflozin benefit in acute heart failure

Starting empagliflozin as soon as feasible after hospital admission for acute heart failure reduces symptom burden and the risk for repeat episodes and mortality over the following 3 months, report the EMPULSE investigators.